Management team


CEO / CSO. Doctor in Biopharmaceutical Sciences.

Siem obtained his PhD in medical pharmacology in 2008 at the University of Leiden, the Netherlands. Entrepreneurial scientist, he contributed to over 25 publications and 6 patents. His career has been in science management in top-end research facilities in Australia, the Netherlands and France. He has conducted research and managed teams in both public research institutes and biotechnology company.


COO. Doctor in Life Sciences.

Khaled obtained his PhD in biology in 2010 at the University Pierre and Marie Curie, Paris, France. After a post-doctorate in biology and biochemistry at the Centre of Research in Cell Biology of Montpellier, he completed a master in business administration at the University School of Management of Montpellier (IAE). He was previously marketing innovation analyst at Horiba Medical, a world leader of in vitro diagnostics, where he defined commercial value of new medical innovations, and liaised with KOLs to understand unmet needs in clinical care.

Operational team


Biochemist and bioinformatician

Guillaume is a seasoned protein biochemist trained to microtubule biochemistry in the ‘Tubulin code’ team at the Institute of Human Genetics (IGH) in Montpellier. He masters microtubule (MT) related biochemistry and further developed skills in bio-informatics applied to drug design. Guillaume has over 10 years applied biochemistry expertise and worked in governmental research organizations, SMEs and large companies.


Molecular and cellular biologist

Yoann is a skilled molecular and cellular biologist trained in academic, hospital and industry settings where he conducted R&D programs and medical analysis for over 10 years. He is trained as microtubule biologist at the Institute of Human Genetics (IGH) in Montpellier and has been key to the initial maturation program. Yoann is knowledgeable in laboratory automation and in implementation of screening methodologies.


Chemical engineer

Zoé is a freshly graduated chemist from the Ecole Nationale Supérieure de Chimie, Biologie et Physique de Bordeaux (ENSCBP). She has multiple professional experience within the pharmaceutical sector both in France and in The Netherlands.

Anthony FERAL

Medicinal chemist

Anthony is a trained medicinal chemist with deep understanding of molecular modelling and compound optimisation. Prior joining MT-act he has been working as a medchem engineer on the development of potent and selective compounds.



Laura is an IBIS Master's student at Montpellier University. This training prepares students to work in (i) biology and health research in public and private institutions, or (ii) technical and regulatory professions, healthcare and pharmaceutical biotechnology and clinical trials. This program provides a transdisciplinary training and is supported by the Faculties of Medicine, Pharmacy and Science of the University of Montpellier.

Chemistry advisors


Medicinal chemist - CNRS director

Muriel obtained her PhD in Organic Chemistry at the University of Montpellier under the supervision of Prof Jean Martinez in 1991. She joined the group of Dr. Paul Anderson at Merck Sharp & Dohm in West point (Pennsylvania, USA) as a non-permanent researcher fellow. In 1996, she started a permanent position at the Laboratory of Amino Acid Peptide and Protein in Montpellier as a CNRS researcher. She became a CNRS senior researcher and a team leader at the Institute of Biomolecules Max Mousseron (IBMM) in 2007. She is currently deputy director of IBMM. Muriel has been collaborating with the team since 2018 and advises on medicinal chemistry.


Medicinal chemist

Lubomir performed his studies in Bulgaria and arrived in Montpellier in 2005 for his masters at the ENSCM engineering school. Then, he performed a co-tutoring PhD between the universities of Montpellier and Naples, which he graduated from in 2011. Afterwards, he did a post-doctoral internship in the prof. Robert Young group in Simon Fraser University, Vancouver, Canada, where he took part in the development of one the first specific autophagy inhibitors. Lubomir moved back to Montpellier, and in 2016, he received an associate professor position at ENSCM in team 9 of the IBMM research institute. He actively collaborates with MT-act to develop best possible compounds for both R&D use and pharmaceutical application.

We gathered an international advisory board with key opinion leaders in pharmaceutical sciences, chemistry and medicine to guide our decisions and advise on our program.